Pfizer (PFE) Income from Non-Controlling Interests (2016 - 2025)
Historic Income from Non-Controlling Interests for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $9.0 million.
- Pfizer's Income from Non-Controlling Interests rose 1250.0% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.0 million, marking a year-over-year increase of 2812.5%. This contributed to the annual value of $31.0 million for FY2024, which is 2051.28% down from last year.
- Pfizer's Income from Non-Controlling Interests amounted to $9.0 million in Q3 2025, which was up 1250.0% from $18.0 million recorded in Q2 2025.
- In the past 5 years, Pfizer's Income from Non-Controlling Interests ranged from a high of $26.0 million in Q3 2021 and a low of $6.0 million during Q2 2022
- Over the past 5 years, Pfizer's median Income from Non-Controlling Interests value was $9.0 million (recorded in 2021), while the average stood at $10.6 million.
- In the last 5 years, Pfizer's Income from Non-Controlling Interests soared by 22500.0% in 2021 and then tumbled by 7692.31% in 2022.
- Pfizer's Income from Non-Controlling Interests (Quarter) stood at $12.0 million in 2021, then grew by 25.0% to $15.0 million in 2022, then crashed by 40.0% to $9.0 million in 2023, then fell by 11.11% to $8.0 million in 2024, then increased by 12.5% to $9.0 million in 2025.
- Its last three reported values are $9.0 million in Q3 2025, $18.0 million for Q2 2025, and $6.0 million during Q1 2025.